Private company

Healthcare AI Acquisition Corp.

Healthcare AI Acquisition Corp. is a blank check company.1 It is headquartered in Albany, New York.1

Last updated Oct 20, 2026.

Overview

  • IndustryBlank Checks1
  • HeadquartersAlbany, New York1
  • Business address418 Broadway #6434, Albany, Ny 122072
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Healthcare AI Acquisition Corp. (referred to herein as the “ Company ” or “ HAIA ”) is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this Report as our initial business combination. We have not yet entered into a definitive agreement with any specific business combination target.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45-$670.8K in 2024−44% since 2022
-$1.5M-$1.0M-$500.0K02022: -$1.2M-$1.2M20222023: -$1.2M-$1.2M2023−3%2024: -$670.8K-$670.8K2024−43%
Net income45$56.8K in 2024−100% since 2022
0$5.0M$10.0M$15.0M2022: $12.8M$12.8M20222023: $4.3M$4.3M2023−66%2024: $56.8K$56.8K2024−99%
Fiscal year20212022202320242025
Operating income-$1.2M4-$1.2M5-$670.8K5
Net income$12.8M4$4.3M5$56.8K5

Compare Healthcare AI Acquisition Corp. with another company

Corporate structure

Healthcare AI Acquisition Corp. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Healthcare AI Acquisition Corp.

  • METEORA CAPITAL, LLC Filed SCHEDULE 13G/A on Healthcare AI Acquisition Corp., latest Aug 14, 2025 (5 filings since Nov 14, 2024)
  • Healthcare AI Acquisition LLC Filed SC 13G on Healthcare AI Acquisition Corp., latest Feb 13, 2024 (2 filings since Feb 11, 2022)
  • ARISTEIA CAPITAL, L.L.C. Filed SC 13G/A on Healthcare AI Acquisition Corp., latest Feb 12, 2024 (2 filings since Feb 13, 2023)
  • CANTOR FITZGERALD SECURITIES Filed SC 13G/A on Healthcare AI Acquisition Corp., latest Feb 12, 2024 (3 filings since Nov 2, 2022)
  • Saba Capital Management, L.P. Filed SC 13G/A on Healthcare AI Acquisition Corp., latest Feb 8, 2024 (4 filings since Dec 20, 2021)
  • HIGHBRIDGE CAPITAL MANAGEMENT LLC Filed SC 13G/A on Healthcare AI Acquisition Corp., latest Jan 19, 2024 (2 filings since Feb 2, 2023)
  • Atticus Ale, LLC Filed SC 13D on Healthcare AI Acquisition Corp., latest Dec 28, 2023
  • Healthcare AI Acquisition Corp. Albany, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Healthcare AI Acquisition Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

Our executive offices are located at 8 The Green, Ste 15614, Dover DE 19901, and our telephone number is (917) 446-0469. Commencing on the date that the Company’s securities were first listed on Nasdaq through the earlier of the consummation of the initial business combination and the Company’s liquidation, the Company began to reimburse the former sponsor for office space, administrative and support services provided to the Company in the amount of $10,000 per month. Upon completion of an initial business combination or the Company’s liquidation, the Company will cease paying these monthly fees.

Item 2 of the 10-K filed Mar 3, 2025.3

Leadership

Who has led Healthcare AI Acquisition Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Simon Lyall-Cottle2021
  2. Zikang Wu2023
  3. Jiande Chen2023

Chief financial officer

  1. Patrick Hargutt2021
  2. Xiaocheng Peng2023
2025
Board members and other officers (16)

Timeline

  1. May 12, 20268-K New debt or obligation25
  2. Nov 19, 20258-K Other events26
  3. Oct 29, 20258-K Shareholder vote27
  4. Oct 14, 20258-K Bylaws or fiscal year changed; Shareholder vote28
  5. Sep 29, 20258-K Other events29
  6. Aug 20, 20258-K New debt or obligation30
  7. May 30, 20258-K New debt or obligation31
  8. May 6, 20258-K Bylaws or fiscal year changed; Shareholder vote; Other events32
  9. Apr 17, 20258-K Other events33
  10. Apr 7, 20258-K Regulation FD disclosure34
  11. Mar 20, 20258-K Other events35
  12. Feb 18, 20258-K Other events36
  13. Dec 28, 2023New chief executive Jiande Chen becomes CEO10
  14. Jun 14, 2023New chief executive Zikang Wu becomes CEO9
  15. Dec 10, 2021New chief executive Simon Lyall-Cottle becomes CEO11

Filings

145 filings to the SEC since October 2021: 6 annual reports, 13 quarterly reports, 37 major events, 25 insider forms, 19 large holders, 45 other. The latest 20:

  1. Sep 30, 2026DEF 14A EDGAR
  2. Sep 17, 2026PRE 14A EDGAR
  3. May 12, 20268-K EDGAR
  4. Nov 19, 20258-K EDGAR
  5. Nov 14, 2025NT 10-Q EDGAR
  6. Nov 13, 202510-Q EDGAR
  7. Oct 29, 20258-K/A EDGAR
  8. Oct 14, 20258-K EDGAR
  9. Sep 30, 2025DEFA14A EDGAR
  10. Sep 29, 20258-K EDGAR
  11. Sep 29, 2025DEFA14A DEFA 14A EDGAR
  12. Sep 17, 2025DEF 14A EDGAR
  13. Sep 5, 2025PRE 14A EDGAR
  14. Aug 20, 20258-K EDGAR
  15. Aug 14, 2025SCHEDULE 13G/A EDGAR
  16. Aug 13, 2025NT 10-Q EDGAR
  17. Jun 5, 202510-Q EDGAR
  18. May 30, 20258-K EDGAR
  19. May 16, 2025NT 10-Q EDGAR
  20. May 15, 2025SCHEDULE 13G/A EDGAR

The 145 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Healthcare AI Acquisition Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARHealthcare AI Acquisition Corp.1
  • CIK0001848861
  • Employer ID (EIN)98-15854503
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inCayman Islands3
  • Fiscal year endsDecember 311
  • Industry code (SIC)6770 Blank Checks1
  • SEC reviewing officeOffice of Real Estate & Construction, Division of Corporation Finance1
  • Business address418 Broadway #6434, Albany, NY 122071
  • Phone917-446-04691
  • Shares outstanding5,543,110 as of Nov 11, 20257
  • Public float$6.7M as of Jun 30, 20243
  • AuditorBush & Associates CPA LLC, Henderson, Nevada PCAOB ID 6797; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMar 19, 20211
  • Filings150 in all: 8-K (35), 3 (20), 10-Q (11), NT 10-Q (8), SC 13G/A (8), DEFA14A (7), SC 13G (7), DEF 14A (6)1
    All 31 form types

    PRE 14A (6), 4 (5), 10-K (4), CORRESP (4), DRS/A (3), SCHEDULE 13G/A (3), UPLOAD (3), 10-K/A (2), 10-Q/A (2), 8-K/A (2), NT 10-K (2), 25-NSE (1), 424B4 (1), 425 (1), 8-A12B (1), CERT (1), DRS (1), EFFECT (1), PRER14A (1), S-1 (1), S-1/A (1), SC 13D (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Mar 3, 2025
    Quarterly report (10-Q) Nov 13, 2025
    Proxy statement (DEF 14A) Sep 30, 2026
    Latest 8-K (8-K) May 12, 2026

Securities registered for trading

ClassSymbolExchange
Units, each consisting of one Class A ordinary share and one-half of one redeemable warrantHAIUF
Class A ordinary shares, par value $0.0001 per shareHAIAF
Warrants, each whole warrant exercisable for one Class A ordinary share, each at an exercise price of $11.50 per shareHAIWF

From the cover page of the 10-K filed Mar 3, 2025 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Healthcare AI Acquisition Corp. names in Item 1A of its 10-K filed Mar 3, 2025: 73 risks under these headings, as written.3

  • You should consider carefully all of the risks described below, together with the other information contained in this Report, including the financial statements. If any of the following risks occur, our business, financial condition or results of operations may be materially and adversely affected. The risk factors described below are not necessarily exhaustive and you are encouraged to perform your own investigation with respect to us and our business.
  • Changes in SEC regulations or policies may adversely impact our ability to negotiate and complete the Business Combination.
  • Risks Related to Being Deemed an Investment Company
  • If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our Business Combination.
  • Risks Relating to our Search for, and Consummation of or Inability to Consummate, a Business Combination
  • Our public shareholders may not be afforded an opportunity to vote on our proposed initial business combination, which means we may complete our initial business combination even if a majority of our public shareholders do not support such a combination.
  • If we seek shareholder approval of our initial business combination, after approval of our board, our sponsor and members of our management team have agreed to vote in favor of such initial business combination, regardless of how our public shareholders vote.
  • Your only opportunity to affect the investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash.
  • The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares may not allow us to complete the most desirable business combination or optimize our capital structure.
  • The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your shares.
  • We may not be able to consummate an initial business combination by June 14, 2025, in which case we would cease all operations except for the purpose of winding up and we would redeem our public shares and liquidate.
  • If we seek shareholder approval of our initial business combination, our sponsor, directors, executive officers, advisors and their affiliates may elect to purchase public shares or warrants, which may influence a vote on a proposed business combination and reduce the public “float” of our Class A ordinary shares or public warrants.
The other 62 risks
  • If a shareholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed.
  • If we seek shareholder approval of our initial business combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a “group” of shareholders are deemed to hold in excess of 15% of our Class A ordinary shares, you will lose the ability to redeem all such shares in excess of 15% of our Class A ordinary shares.
  • Because of our limited resources and the significant competition for business combination opportunities, it may be more difficult for us to complete our initial business combination. If we have not consummated our initial business combination within the required time period, our public shareholders may receive only approximately $10.20 per public share, or less than such amount in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.
  • If the net proceeds of our initial public offering, over-allotment and the sale of the private placement warrants not being held in the trust account are insufficient to allow us to operate until June 14, 2025, it could limit the amount available to fund our search for a target business or businesses and our ability to complete our initial business combination, and we will depend on loans from our sponsor, its affiliates or members of our management team to fund our search and to complete our initial business combination.
  • If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by shareholders may be less than $10.20 per public share.
  • Our directors may decide not to enforce the indemnification obligations of our sponsor, resulting in a reduction in the amount of funds in the trust account available for distribution to our public shareholders.
  • We may not have sufficient funds to satisfy indemnification claims of our directors and executive officers.
  • If, after we distribute the proceeds in the trust account to our public shareholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, a bankruptcy court may seek to recover such proceeds, and the members of our board of directors may be viewed as having breached their fiduciary duties to our creditors, thereby exposing the members of our board of directors and us to claims of punitive damages.
  • If, before distributing the proceeds in the trust account to our public shareholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of our shareholders and the per-share amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced.
  • Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial business combination, and results of operations.
  • If we have not consummated an initial business combination by June 14, 2025, our public shareholders may be forced to wait beyond such 18 months before redemption from our trust account.
  • Our shareholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption of their shares.
  • Holders of Class A ordinary shares will not be entitled to vote on any election of directors we hold prior to our initial business combination.
  • Because we are neither limited to evaluating a target business in a particular industry, sector or geographic area nor have we entered into a definitive agreement with any specific target businesses with which to pursue our initial business combination, you will be unable to ascertain the merits or risks of any particular target business’s operations.
  • We may seek business combination opportunities in industries, sectors or geographies which may or may not be outside of our management’s area of expertise.
  • Although we have identified general criteria and guidelines that we believe are important in evaluating prospective target businesses, we may enter into our initial business combination with a target that does not meet such criteria and guidelines, and as a result, the target business with which we enter into our initial business combination may not have attributes entirely consistent with our general criteria and guidelines.
  • We are not required to obtain an opinion from an independent accounting or investment banking firm, and consequently, you may have no assurance from an independent source that the price we are paying for the business is fair to our shareholders from a financial point of view.
  • We may issue additional Class A ordinary shares or preference shares to complete our initial business combination or under an employee incentive plan after completion of our initial business combination. We may also issue Class A ordinary shares upon the conversion of the founder shares at a ratio greater than one-to-one at the time of our initial business combination as a result of the anti-dilution provisions contained in our amended and restated memorandum and articles of association. Any such issuances would dilute the interest of our shareholders and likely present other risks.
  • Unlike some other similarly structured blank check companies, our sponsor will receive additional Class A ordinary shares if we issue shares to consummate an initial business combination.
  • Resources could be wasted in researching business combinations that are not completed, which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we have not consummated our initial business combination within the required time period, our public shareholders may receive only approximately $10.20 per public share, or less than such amount in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.
  • We may engage in a business combination with one or more target businesses that have relationships with entities that may be affiliated with our sponsor, executive officers, directors or initial shareholders which may raise potential conflicts of interest.
  • Since our sponsor, executive officers and directors will lose their entire investment in us if our initial business combination is not completed, a conflict of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination.
  • Our independent registered public accounting firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.”
  • We may issue notes or other debt securities, or otherwise incur substantial debt, to complete an initial business combination, which may adversely affect our leverage and financial condition and thus negatively impact the value of our shareholders’ investment in us.
  • We may only be able to complete one business combination with the proceeds of our initial public offering, over-allotment and the sale of the private placement warrants, which will cause us to be solely dependent on a single business which may have a limited number of products or services. This lack of diversification may negatively impact our operations and profitability.
  • In order to effectuate an initial business combination, blank check companies have, in the recent past, amended various provisions of their charters and other governing instruments, including their warrant agreements. We cannot assure you that we will not seek to amend our amended and restated memorandum and articles of association or governing instruments in a manner that will make it easier for us to complete our initial business combination that our shareholders may not support.
  • We may be unable to obtain additional financing to complete our initial business combination or to fund the operations and growth of a target business, which could compel us to restructure or abandon a particular business combination. If we have not consummated our initial business combination within the required time period, our public shareholders may receive only approximately $10.20 per public share, or less than such amount in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.
  • Our sponsor controls a substantial interest in us and thus may exert a substantial influence on actions requiring a shareholder vote, potentially in a manner that you do not support.
  • Compliance obligations under the Sarbanes-Oxley Act may make it more difficult for us to effectuate a business combination, require substantial financial and management resources, and increase the time and costs of completing a business combination.
  • Risks Relating to the Post-Business Combination Company
  • Subsequent to our completion of our initial business combination, we may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and the price of our securities, which could cause you to lose some or all of your investment.
  • The officers and directors of an initial business combination candidate may resign upon completion of our initial business combination. The loss of an initial business combination target’s key personnel could negatively impact the operations and profitability of our post-combination business.
  • Risks Associated with Acquiring and Operating a Business in Foreign Countries
  • Leading Group has operations or opportunities outside of the United States for our initial business combination, so we may face additional burdens in connection with investigating, agreeing to and completing such initial business combination, and if we effect such initial business combination, we would be subject to a variety of additional risks that may negatively impact our operations.
  • We may reincorporate in another jurisdiction in connection with our initial business combination and such reincorporation may result in taxes imposed on shareholders.
  • We may reincorporate in another jurisdiction in connection with our initial business combination, and the laws of such jurisdiction may govern some or all of our future material agreements and we may not be able to enforce our legal rights.
  • We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of non-compliance.
  • If our management following our initial business combination is unfamiliar with United States securities laws, they may have to expend time and resources becoming familiar with such laws, which could lead to various regulatory issues.
  • After our initial business combination, substantially all of our assets may be located in a foreign country and substantially all of our revenue may be derived from our operations in any such country. Accordingly, our results of operations and prospects will be subject, to a significant extent, to the economic, political and social conditions and government policies, developments and conditions in the country in which we operate.
  • Exchange rate fluctuations and currency policies may cause a target business’ ability to succeed in the international markets to be diminished.
  • Risks Relating to our Management Team
  • We are dependent upon our executive officers and directors, and their loss could adversely affect our ability to operate.
  • Our ability to successfully effect our initial business combination and to be successful thereafter will be dependent upon the efforts of our key personnel, some of whom may join us following our initial business combination. The loss of key personnel could negatively impact the operations and profitability of our post-combination business.
  • Our key personnel may negotiate employment or consulting agreements with a target business in connection with a particular business combination, and a particular business combination may be conditioned on the retention or resignation of such key personnel. These agreements may provide for them to receive compensation following our initial business combination and as a result, may cause them to have conflicts of interest in determining whether a particular business combination is the most advantageous.
  • Our executive officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our initial business combination.
  • Our officers and directors presently have, and any of them in the future may have, additional fiduciary or contractual obligations to other entities, including another blank check company, and, accordingly, may have conflicts of interest in determining to which entity a particular business opportunity should be presented.
  • Our executive officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests.
  • Risks Relating to our Securities
  • You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss.
  • Because we are incorporated under the laws of the Cayman Islands, you may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. federal courts may be limited.
  • After our initial business combination, it is possible that a majority of our directors and officers will live outside the United States and all of our assets will be located outside the United States; therefore investors may not be able to enforce federal securities laws or their other legal rights.
  • Provisions in our amended and restated memorandum and articles of association may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our Class A ordinary shares and could entrench management.
  • Since only holders of our founder shares will have the right to vote on the election of directors, upon the listing of our shares on Nasdaq, Nasdaq may consider us to be a “controlled company” within the meaning of Nasdaq rules and, as a result, we may qualify for exemptions from certain corporate governance requirements.
  • We may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with the approval by the holders of at least 50% of the then-outstanding public warrants. As a result, the exercise price of your warrants could be increased, the exercise period could be shortened and the number of our Class A ordinary shares purchasable upon exercise of a warrant could be decreased, all without your approval.
  • Our warrant agreement designates the courts of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants, which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our company.
  • A provision of our warrant agreement may make it more difficult for us to consummate an initial business combination.
  • We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.
  • Because each unit contains one-half of one redeemable warrant and only a whole warrant may be exercised, the units may be worth less than units of other blank check companies.
  • We are not registering the Class A ordinary shares issuable upon exercise of the warrants under the Securities Act or any state securities laws at this time, and such registration may not be in place when an investor desires to exercise warrants, thus precluding such investor from being able to exercise its warrants except on a cashless basis and potentially causing such warrants to expire worthless.
  • The warrants may become exercisable and redeemable for a security other than the Class A ordinary shares, and you will not have any information regarding such other security at this time.
  • The grant of registration rights to our sponsor may make it more difficult to complete our initial business combination, and the future exercise of such rights may adversely affect the market price of our Class A ordinary shares.
  • General Risk Factors
  • We have no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.
  • Past performance by our directors, our management team or their respective affiliates may not be indicative of future performance of an investment in us.
  • Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss.
  • We may be a passive foreign investment company, or “PFIC,” which could result in adverse U.S. federal income tax consequences to U.S. investors.
  • We are an emerging growth company and a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to “emerging growth companies” or “smaller reporting companies,” this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.

Legal proceedings

To the knowledge of our management, there is no material litigation, arbitration or governmental proceeding currently pending or contemplated against us, any of our officers or directors in their capacity as such or against any of our property.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43